Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
City AM
—
— 26 Abstracts Accepted Demonstrate Alkermes’ Commitment to Advancing Understanding and Treatment of Narcolepsy and Idiopathic Hypersomnia — — Detailed Positive Results from Vibrance-2 Phase 2 Study of Alixorexton, an Orexin 2 Receptor Agonist, in Patients With Narcolepsy Type 2 to be Shared in Oral Presentation —